AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 31.92 |
Market Cap | 4.85B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -5.16 |
PE Ratio (ttm) | -6.17 |
Forward PE | n/a |
Analyst | Buy |
Ask | 32.2 |
Volume | 3,841,908 |
Avg. Volume (20D) | 2,550,296 |
Open | 33.10 |
Previous Close | 32.34 |
Day's Range | 31.66 - 34.62 |
52-Week Range | 22.89 - 79.49 |
Beta | undefined |
About TEM
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-iden...
Analyst Forecast
According to 11 analyst ratings, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 72.77% from the latest price.
2 months ago · seekingalpha.com
Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven InnovationTempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecul...